Head to Head Analysis: Bullfrog AI (NASDAQ:BFRG) and American Well (NYSE:AMWL)

American Well (NYSE:AMWL) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Valuation and Earnings

This table compares American Well and Bullfrog AI”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Well	$249.32 million	0.61	-$95.70 million	($5.42)	-1.69
Bullfrog AI	$120,000.00	95.48	-$6.50 million	($0.54)	-1.14

Bullfrog AI has lower revenue, but higher earnings than American Well. American Well is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares American Well and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
American Well	-37.02%	-32.11%	-24.12%
Bullfrog AI	N/A	-217.80%	-174.57%

Insider and Institutional Ownership

56.1% of American Well shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 12.8% of American Well shares are held by company insiders. Comparatively, 25.2% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

American Well has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.89, suggesting that its share price is 389% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for American Well and Bullfrog AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Well	1	3	1	0	2.00
Bullfrog AI	1	0	0	0	1.00

American Well currently has a consensus target price of $7.20, suggesting a potential downside of 21.22%. Given American Well’s stronger consensus rating and higher possible upside, research analysts plainly believe American Well is more favorable than Bullfrog AI.

Summary

American Well beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.